The JN.1 Variant of SARS-CoV-2: Public Health Alert or Controlled Threat?

The recent global rise in cases associated with the JN.1 variant of SARS-CoV-2, a sub lineage of the Omicron variant, calls for urgent scholarly and public health attention. Identified initially in late 2023, JN.1 has rapidly gained prevalence and, by early 2024, became the most dominant circulating strain globally, according to the Centres for Disease Control and Prevention (CDC) (1). As of mid-December 2023, JN.1 was detected in 41 countries, constituting over 27% of global sequences submitted to GISAID (2). Its increasing dominance can be attributed to mutations that confer heightened transmissibility and partial immune evasion. Despite this, available evidence suggests that JN.1 does not lead to more severe disease outcomes compared to its predecessors (1,3).